CagriSema is one weekly injection carrying two appetite-regulating drugs, cagrilintide and semaglutide, and its phase 3 results are clinically strong but smaller than the market had priced in. The weight-loss evidence sits at the human clinical tier, the strongest level available, yet none of it has produced a regulatory label: the combination remains investigational and cannot be legally prescribed or purchased in the United States. Anything sold under that name outside a clinical trial is not the studied medicine.
CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, produced 20.4 percent average weight loss over 68 weeks in REDEFINE 1 and holds no FDA approval.
The name is a contraction of its two ingredients, and that contraction is the whole product: one co-formulated solution instead of two separate shots. What separates it from a clinician layering two branded drugs is a single titration schedule and a single prescription, which is a practical difference rather than a pharmacological one.
CagriSema combines cagrilintide, a long-acting amylin analog, with semaglutide, an approved GLP-1 receptor agonist, at 2.4 mg of each component in a single weekly subcutaneous injection.
Two appetite systems are being pushed at once, which is the entire scientific premise of the product. Amylin acts largely through hindbrain satiation circuits while GLP-1 works on hypothalamic and brainstem appetite pathways alongside glucose-dependent insulin secretion, and those circuits overlap only partly. That partial overlap is the argument for why the ceiling of a maximally dosed GLP-1 drug is not the ceiling of appetite suppression overall.
| Property | Cagrilintide (amylin analog) | Semaglutide (GLP-1 agonist) |
|---|---|---|
| Native hormone | Amylin, co-secreted with insulin | GLP-1, released from the gut |
| Primary appetite site | Hindbrain satiation circuits | Hypothalamic and brainstem circuits |
| Other metabolic action | Slows gastric emptying, blunts post-meal glucagon | Glucose-dependent insulin secretion, glucagon suppression |
| Half-life engineering | Fatty acid side chain binding albumin | Acylation supporting about one week |
Amylin and GLP-1 suppress appetite through only partly overlapping central circuits, and the reported improvement in leptin sensitivity from amylin analogs rests on preclinical and early clinical work rather than demonstrated human outcomes.
The headline number from REDEFINE 1 was clinically strong and commercially disappointing at the same time, and the gap between those two readings accounts for most of the coverage the drug received. This is phase 3 human evidence, the strongest tier, but it has been reported as topline and conference-stage data rather than full peer-reviewed publication.
Among REDEFINE 1 participants who stayed on treatment, 60.2 percent lost at least 20 percent of body weight and 40.4 percent lost at least 25 percent, while the 20.4 percent trial average still landed below the roughly 25 percent analysts had projected.
Only one kind of comparison in this category holds up, and that is a head-to-head trial run in the same patients under the same protocol. REDEFINE 4 supplied exactly that against tirzepatide, and the combination lost: 23.0 percent against 25.5 percent over 84 weeks, missing its primary endpoint of non-inferiority. Cross-trial comparisons of everything else move by several percentage points on baseline weight, titration rules, and estimand definitions alone, which is why they carry little weight in a prescribing decision.
| Measure | CagriSema | Tirzepatide 15 mg | Semaglutide 2.4 mg |
|---|---|---|---|
| Head-to-head result | 23.0% (REDEFINE 4, 84 weeks) | 25.5% (same trial) | 14.9% (REDEFINE 1, 68 weeks) |
| Primary endpoint | Non-inferiority not achieved | Active comparator | Beaten in-trial by the combination |
| Mechanisms | Amylin plus GLP-1 | GIP plus GLP-1 | GLP-1 alone |
| Outcome trial record | None yet | Accumulated | Cardiovascular and kidney trials |
In the 84-week REDEFINE 4 head-to-head trial, CagriSema produced 23.0 percent average weight loss against 25.5 percent for tirzepatide 15 mg and did not meet its primary non-inferiority endpoint.
Gastrointestinal effects dominate the reported safety picture, as they do across the incretin class, and the figure that deserves more attention than the average weight loss is the share of participants who discontinued for adverse events. A drug nobody can stay on for a year does not deliver its trial result in practice. The question specific to this product is whether stacking two mechanisms that both slow gastric emptying compounds nausea rather than simply adding efficacy.
Nausea, vomiting, diarrhea, and constipation were the most frequently reported adverse events across the phase 3 CagriSema program, and no complete safety profile exists until a regulator reviews the full dataset and publishes a label.
The status that matters is the simplest one: CagriSema is investigational, unapproved by the US Food and Drug Administration, and unavailable through any legitimate commercial channel. Novo Nordisk has moved into regulatory submission with the obesity indication filed ahead of the diabetes indication, since the two are reviewed as separate applications carrying separate evidence packages.
CagriSema carries no marketing authorization from the FDA or any other major regulator, so material sold under that name as research chemical, compounded preparation, or gray-market import is not the studied product and carries no assurance of identity, purity, sterility, or dose.
Administration in the trials followed the pattern the incretin class made familiar: a once-weekly subcutaneous injection from a prefilled pen delivering both peptides in one co-formulated solution. Every specific below is provisional, because authoritative dosing instructions do not exist until a regulator approves a label, and trial protocols and final labels routinely differ.
The pivotal CagriSema program escalated gradually toward a 2.4 mg plus 2.4 mg once-weekly subcutaneous maintenance dose while permitting dose adjustment, so the reported trial average blends participants who finished at different doses.
No approved label exists, so trial eligibility is the closest available proxy for who an eventual indication would cover. The enrollment thresholds match the structure already used for approved obesity medicines, and the exclusion lists shape real-world caution more than they get discussed.
CagriSema's phase 3 weight-management trials enrolled adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition, the same threshold structure used by currently approved obesity medicines.
Obesity is treated as a chronic, relapsing condition across this entire drug class, so the working expectation is indefinite treatment rather than a course with an endpoint. Withdrawal studies of semaglutide and of tirzepatide both showed participants regaining a large share of lost weight within roughly a year of stopping, along with the return of blood pressure and lipid numbers. Neither amylin nor GLP-1 changes the underlying physiology permanently, so there is no mechanistic reason to expect the combination to behave differently.
The longest reported CagriSema exposure is the 84-week REDEFINE 4 trial, so no multi-year durability evidence exists for this combination, while withdrawal studies of semaglutide and tirzepatide both document substantial regain within about a year of stopping.
No price exists because no approved product exists, which leaves the category itself as the only usable reference. Branded incretin obesity drugs in the United States have carried list prices roughly between 1,000 and 1,350 dollars per month, with actual patient cost swinging enormously on rebates, employer plan design, savings cards, and direct cash-pay programs. The cost most often underweighted sits on the other side of stopping, since documented regain means a course that cannot be sustained buys a temporary result at full price.
| Payer | Weight-loss indication | Approved comorbidity indication |
|---|---|---|
| Commercial plans | Often excluded or prior-authorization gated | Generally broader |
| Medicare Part D | Barred by statute; 50 dollars monthly via the temporary GLP-1 Bridge program through 31 December 2027 | Covered for type 2 diabetes or cardiovascular risk reduction |
| Medicaid | Varies state by state | Varies state by state |
Branded incretin obesity drugs list at roughly 1,000 to 1,350 dollars per month in the United States, and Medicare Part D remains barred by statute from covering weight-loss-only use outside the temporary GLP-1 Bridge program offering a 50 dollar monthly copayment through 31 December 2027.
Educational use only. This article describes what the published scientific and clinical literature reports about CagriSema. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
